Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells

Stem Cells

Volumn 26, Issue 11, 2008, Pages 2955-2963

  Secchiero, Paola ^a   Melloni, Elisabetta ^a   Corallini, Federica ^a   Beltrami, Antonio Paolo ^b   Alviano, Francesco ^c   Milani, Daniela ^a   D'Aurizio, Federica ^b   Di Iasio, Maria Grazia ^a   Cesselli, Daniela ^b   Bagnara, Gian Paolo ^c   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Mesenchymal stem cells; Migration; Multipotent precursor; Tumor necrosis factor related apoptosis inducing ligand; Tumor necrosis factor related apoptosis inducing ligand receptors

Indexed keywords

DEATH RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; OSTEOBLAST; PROTEIN PHOSPHORYLATION; STROMA CELL;

BONE MARROW CELLS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MESENCHYMAL STEM CELLS; PHOSPHORYLATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

ADENOVIRIDAE;

EID: 56249123994     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0512     Document Type: Article

References (40)

1. Gibellini D, Borderi M, De Crignis E et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naïve HIV-1 positive men. J Med Virol 2007;79:1446-1454.
2. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006;17:245-257.
3. Takeda K, Stagg J, Yagita H et al. Targeting death-inducing receptors in cancer therapy. Oncogene 2007;26:3745-3757.
4. Bu R, Borysenko CW, Li Y et al. Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 2003;33:760-770.
5. Tinhofer I, Biedermann R, Krismer M et al. A role of TRAIL in killing osteoblasts by myeloma cells. FASEB J 2006;20:759-761.
6. Sharrow AC, Li Y, Cicsenyi A et al. Modulation of osteoblast gap junction connectivity by serum, TNF-alpha, and TRAIL. Exp Cell Res 2008;314:297-308.
7. Alviano F, Fossati V, Marchionni C et al. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol 2007;7:11-25.
8. Ventura C, Cantoni S, Bianchi F et al. Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted hearts. J Biol Chem 2007;282:14243-14252.
9. Zauli G, Rimondi E, Nicolin V et al. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 2004;104:2044-2050.
10. Secchiero P, Barbarotto E, Tiribelli M et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:4122-4129.
11. Griffith TS, Anderson RD, Davidson BL et al. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886-2894.
12. Ponte AL, Marais E, Gallay N et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. STEM CELLS 2007;25:1737-1745.
13. Croitoru-Lamoury J, Lamoury FM, Zaunders JJ et al. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta and copaxone. J Interferon Cytokine Res 2007;27:53-64.
14. Secchiero P, Gonelli A, Carnevale E et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003;107:2250-2256.
15. Secchiero P, Melloni E, Heikinheimo M et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004;103:517-522.
16. Beltrami AP, Cesselli D, Bergamin N et al. Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow). Blood 2007;110:3438-3446.
17. Pasquinelli G, Tazzari PL, Vaselli C et al. Thoracic aortas from multi-organ donors are suitable for obtaining resident angiogenic mesenchymal stromal cells. STEM CELLS 2007;25:1627-1634.
18. Li L, Neaves WB. Normal stem cells and cancer stem cells: The niche matters. Cancer Res 2006;66:4553-4537.
19. Sacchetti B, Funari A, Michienzi S et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007;131:324-336.
20. Campioni D, Secchiero P, Corallini F et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005;166:557-563.
21. Kakagianni T, Giannakoulas NC, Thanopoulou E et al. A probable role for Trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res 2006;30:713-721.
22. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007;211:27-35.
23. Jacob D, Davis JJ, Zhang L et al. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 2005;12:109-115.
24. Mohr A, Lyonsb M, Deedigan L et al. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008 [Epub ahead of print].
25. Cassatella MA, Huber V, Calzetti F et al. Interferon-activated neutrophils store a TNF-related apoptosis inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. J Leukoc Biol 2006;79:123-132.
26. Chamberlain G, Fox J, Ashton B et al. Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features and potential for homing. STEM CELLS 2007;25:2739-2749.
27. Okitsu Y, Takahashi S, Minegishi N et al. Regulation of adipocyte differentiation of bone marrow stromal cells by transcription factor GATA-2. Biochem Biophys Res Commun 2007;364:383-387.
28. Gurevitch O, Slavin S, Feldman AG. Conversion of red bone marrow into yellow - Cause and mechanisms. Med Hypotheses 2007;69:531-536.
29. Secchiero P, Gonelli A, Mirandola P et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002;100:2421-2429.
30. Fox JM, Chamberlain G, Ashton BA et al. Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol 2007;137:491-502.
31. Honczarenko M, Le Y, Swierkowski M et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. STEM CELLS 2006;24:1030-1041.
32. Shi M, Li J, Liao L et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. Haematologica 2007;92:897-904.
33. Menon LG, Picinich S, Koneru R et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. STEM CELLS 2007;25:520-528.
34. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Science 2004;117:4619-4628.
35. Meriane M, Duhamel S, Lejeune L et al. Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stroma cells. STEM CELLS 2006;24:2557-2565.
36. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-49.
37. Secchiero P, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008;15:42-48.
38. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-1603.
39. Zipori D. The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer Metastasis Rev 2006;25:459-467.
40. Secchiero P, Zerbinati C, Rimondi E et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004;61:1965-1974.